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Abstract
Stem cells therapeutics has come a long way since stem cells and their potential was discovered for the first time.
Intense research into cellular biology of stem cells has revealed that they possess immense potential for curing
many human diseases. Research done in last couple of decades revealed that a particular class of stem cells
called, “Human embryonic stem cells (HESCs)” possessed exceptional self-renewal and pluripotency properties.
There ability to differentiate into specialized cell lineages of all three embryonic germ layers contributed further
towards their popularity. However, in recent times HESCs have come under the cross-hairs of critics, politicians
and religious groups due to certain technical and ethical concerns related to them. Such problems with HESCs-
research have forced stem cell researchers to start exploring the prospects of using alternatives to HESCs for
regenerative medicine and therapeutics. In the present review, various sources of stem cells have been described,
which in near future, have the potential to replace HESCs in regenerative medicine.
Introduction
Stem cells have emerged as a revolution in the field of regenerative medicine. In last couple of decades,
intense stem cell research has given us important insights into nature of these cells and their potential for
organ formation as well as regeneration and repair after injuries (National-Academy-of-Sciences, 2002).
Tissue repair systems in mammals are mostly based upon dedifferentiation-independent processes
regulated and governed through pre-existing stem cells or progenitor cells, which is the reason why stem
cells have been at the heart of regenerative medicine. Regenerative medicine deals with all the tissues in
human body, which was the reason why stem cells having the capability of differentiating into any type of
human tissue cell with considerable capacity were required. Human embryonic stem cells (HESCs) were
found to live up to this requirement, since they exhibited the properties of indefinite self-renewal and
pluripotency (National-Academy-of-Sciences, 2002). Over a period of time, it has been proved that
HESCs can differentiate into specialized cell lineages of all three embryonic germ layers in relatively
simplified cultures, thereby contributing further towards their popularity. However, even though HESCs
hold tremendous promise there are certain major ‘technical' obstacles in the successful and safe clinical
application of these cells (National-Academy-of-Sciences, 2002). Firstly, the cell differentiation factors
responsible for tissue-specific differentiation of HESCs are not fully characterized. Secondly, there is a
good possibility of HESCs derived cells facing immune rejection from the recipient's body. Moreover there
is also a risk of these cells driving the production of teratoma or teratocarcinomas. Lastly, the use of
HESCs has received severe ethical criticism since cultivation of HESCs involves destruction of an embryo,
which is religiously considered to be a potential human-being (Reichhardt et al., 2004). While scientific
1
research has been looking forward to solving various risks and limitations associated with HESCs on
behest of its tremendous advantages; yet it has been tough for the researchers to confront the ethical
debate over HESCs, as its driven by philosophical and religious ideologies associated with human
civilization (Pera and Trounson, 2004). These debates and discussions regarding HESCs have finally led
to formulation of stringent laws and crippling of government funds against HESCs-based research (Pera
and Trounson, 2004). Such measures against HESCs-research have forced stem-cell researchers to start
exploring the prospects of using alternatives to HESCs for regenerative medicine. Scientists have been
looking forward to various different alternatives, which can convincingly replace HESCs in regenerative
medicine. In the following sections, various types of cells and strategies, which can be used as
alternatives to HESCs, have been discussed in details.
Pluripotent Aminotic Epithelium Cells (AECs)
Pluripotent amniotic epithelium cells are kind of stem cells derived from the amniotic membrane. Such
stem cell-like cells, have found important application in tissue repair as these cells lack HLA-molecules
on their surface, thereby making them non-immunogenic and ideal for regenerative purpose (Strom and
Miki, 2003). In fact, amniotic membrane material has found good application in treatment of human
corneal injuries (Shimmura and Tsubota, 2002). These amniotic membrane cells have also been reported
to exhibit neural characteristics e.g. expression of nestin, BDNF and dopamine (Kakishita et al., 2003).
These pluripotent AECs have been regarded as one of the most promising alternatives for HESCs in
regenerative medicine (Mimeault et al., 2007).
Trophoblast-derived Stem Cells (TSC)
Trophoblast's portion that is in contact with inner-cell mass (ICM) of the blastocyst has been found to
form extraembryonic ectoderm (ExE) and ectoplacental cone (EPC). Research has found existence of
certain stem cells termed as Trophoblast-derived Stem Cell (TSCs) in the ExE (Tanaka et al., 1998). It
has been found that these TSCs are maintained under the signal from ICM and epiblast. Such TSCs
have been derived mostly from mouse and only recently from Rhesus Monkey (Vandevoort et al., 2007).
Though these TSCs haven't been derived from humans, yet there exists a good chance of them being
discovered in the near future. Potential of TSCs in regenerative medicine hasn't been demonstrated yet
though there is a little bit of scare regarding their role since these are highly invasive and proliferative
cells by nature (Hemberger et al., 2004). We need to wait and watch for more research on TSCs to
assess their potential for regenerative medicine.
Endometrial Regenerative Cells (ERC)
Endometrial Regenerative Stem Cells (ERCs) are small population of stem-cell-like cells in the menstrual
blood, which have been hypothesized to play role in angiogenesis phase of the menstrual cycle in the
endometrium (Bulletin-Board, 2008). Research on the differentiation potential of these cells has shown
that they are capable of differentiating into endodermal (pancreatic, hepatic, respiratory epithelium),
mesodermal (osteocyte, endothelium, adipocyte, myocyte, cardiomyocyte) as well as ectodermal
(neuronal) lineages (Meng et al., 2007). Further research has found that ERCs could be promisingly
propagated beyond 68 doublings while still maintaining their normal karyotype. ERCs have been
demonstrated to have a proliferation rate far better than mesenchymal or umbilical cord stem cells
(Bulletin-Board, 2008) and ability to differentiate into cells representing all 3 germ-layers thereby making
them potential alternative for HESCs (Meng et al., 2007). ERC's biggest advantage over HESCs is the
ease with which these cells may be obtained for creation of patient-specific banking. Potential problems
with ERCs however are that, they haven't been confirmed to be complete stem-cells as their telomerase
activity and certain other surface markers haven't been assessed (Meng et al., 2007). Moreover, based
upon available data the possibility of ERCs giving rise to teratomas may not be ruled out. Thus, since
ERCs are relatively newly discovered cells, we need to wait and watch for more research to confirm
whether these cells could be effectively used in regenerative medicine.
Placental-derived Stem Cells (PDSC)
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Placenta has been reported to contain an important population of multipotent stem cells called Placental-
derived Stem Cells (PDSCs), exhibiting characteristics of HESCs including expression of markers like
OCT-4, SOX-2, SSEA1 as well as c-Kit (Matikainen and Laine, 2005). These cells have been shown to
resemble mesenchymal stem cells and differentiate into various lineages like hepatocyte, vascular-
endothelial, pancreatic and neuronal (Strom and Miki, 2003). PDSCs have also been isolated from
amniotic membrane. PDSCs seem to be promising for regenerative medicine as they are easy to obtain
as well as store yet PDSCs haven't been yet tested in published clinical studies. Moreover, their actual
number in a single placenta hasn't been confirmed. To make matters worse, PDSCs have been found to
possess unusual property of invasiveness (naturally required during embryo-implantation in placenta),
which could increase the threat of teratomas during clinical therapeutic usage. Thus, there is need for
extensive research so as to harness the potential of these stem cells.
Umbilical Cord Blood Stem Cells (UCB-SC)
Umbilical Cord Blood (UCB) has been recognized as a prime source of haematopoietic stem cells for a
long time (Matikainen and Laine, 2005). Biggest advantage of UCB is that, it can be easily collected from
the umbilical vein of the placenta which would be otherwise discarded after the birth. UCB has been
routinely used in treatment of haematopoietic malignancies as an alternative for bone-marrow
transplantation (Grewal et al., 2003). Public cord blood banks have also been set-up in many countries to
collect & store UCB after full-term pregnancies for future patient care. UCB-SCs have been found to be
almost non-immunogenic thereby making them an important asset in regenerative medicine (Matikainen
and Laine, 2005). UCB-SCs have been shown to differentiate into cells representing all 3 germ layers e.g.
osteoblast-, neural-, chondrocyte-, adipocyte- and hepatocyte-like cells (Lee et al., 2004). In certain
diseased mouse-models, UCB-SCs have been shown to assist in recovery from myocardial and hind-limb
ischemia (Botta et al., 2004) as well as in recovery of motor function (Chen et al., 2001). The above
discussion shows that, UCB-SCs may be regarded as potential alternatives to the HESCs in regenerative
medicine. Only drawback however is that when compared to adult stem cells, UCB-SCs have been
involved in a very small number of clinical regeneration investigations. However, in coming years it's
expected that studies on UCB-SCs would place it on fore-front of regenerative-medicine research.
Amniotic Fluid Stem Cells (AFSCs)
Amniotic Fluid Stem Cells (AFSC), as the name suggests are novel cells derived from the amniotic fluid.
Research has revealed that AFSCs could differentiate into at least 6 cellular lineages representing all
three germ layers (De Coppi et al., 2007). AFSCs have been shown to differentiate along, Neural,
Hepatic, Osteogenic, Myogenic, Adipogenic as well as endothelial lineage. AFSCc were also found to
grow stably in culture such that they exhibited property of self-renewal but without presence of
senescence. AFSCs were found to maintain long telomeres beyond 250 population doublings (p.d.),
which exceeds the typical “Hayflick limit” of about 50p.d. (De Coppi et al., 2007). This is quiet a significant
property when compared to ESCs or Adult Stem Cells (ASCs). Potential of AFSCs in regenerative
medicine has also been tested. AFSCs differentiated into neural-lineages and osteogenic-lineages were
transplanted in the brain of a mouse suffering from Twitcher disease and intra-peritoneal cavity of another
mouse respectively. Later it was shown that the respective differentiated AFSCs started healing the brain
as well as started forming bones (De Coppi et al., 2007). Further it has been elucidated that, AFSCs
could be cultured without feeder layers, they have a short doubling time (36hrs), they don't form tumours
and moreover they are obtained from a source (amnion or amniotic fluid) which otherwise would be
discarded (De Coppi et al., 2007). Thus they represent an ‘ethical' and renewable source of stem cells
that could be potentially used as an alternative for HESCs in regenerative medicine (Domestic-Policy-
Council, 2007, Apr 2). The only thing here is that, we need to wait for more research papers and find out
whether the results obtained above are reproducible elsewhere or not.
Adult Stem Cells (ASCs)
Adult Stem Cells (ASCs) are tissue-resident cells found in all mammalian organisms. ASCs carry out a
critical function of maintaining homeostasis in many human-tissues by assisting in wear and tear of the
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body and constantly acting as source of newer mature cells, which take place of old cells. ASCs have
been at the top of the list as alternatives for HESCs in the field of regenerative medicine (Mimeault et al.,
2007). Most well characterized ASCs are Bone-marrow derived stem cells (BMSCs), hematopoietic stem
cells (HSCs), endothelial progenitor cells (EPCs), Mesenchymal Stem Cells (MSCs), Cardiac Stem Cells
(CSCs) and Neural Stem Cells (NSCs) (Mimeault et al., 2007). HSCs are the most classic of all the ASCs
since they have been used in clinical medicine since 1970s (Matikainen and Laine, 2005). MSCs are other
highly promising ASCs, which have ability to differentiate into neuron-like cells, multiple mesodermal-
tissue types like muscle, marrow stroma, tendon, cartilage, bone, fat, ligament and a number of other
connective tissues (Bongso and Richards, 2004). MSCs are currently regarded as the most preferred
choice in patient-specific regenerative medicine since they are pluripotent, easy to culture and have a
favourable doubling time (Bongso and Richards, 2004, Jiang et al., 2002). Various differences between
ASCs and HESCs have been summarized in Table 1.
Table 1: Differences between Human Adult Stem Cells and Human Embryonic Stem Cells (Bongso
and Richards, 2004)
ASCs are definitely less controversial than HESCs. Moreover, there have been 1,373 publicly available
human clinical trials related to ASCs (As of April 2, 2007) while there have been no such trials for HESCs
(Domestic-Policy-Council, 2007, Apr 2), which further adds upto the importance of ASCs. However only
disadvantage of ASCs is that they are scarce and hence hard to isolate and culture. This actually
increases the overall cost and time for the treatment. In next couple of decades, it's expected that the
regenerative-therapy based on ASCs would improve several folds.
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Induced Pluripotent Stem Cells (iPS)
Induced Pluripotent Stem Cells (iPS) are by far the most exciting alternatives proposed for HESCs in the
field of regenerative medicine (Cibelli, 2007). The initiative for the production of these cells was taken
solely with the purpose of circumventing the ethical issues associated with the HESCs (Takahashi et al.,
2007). These iPSs are results of in vitro dedifferentiation wherein certain transcription factors like OCT3/4,
SOX2, KLF4 etc. are used to reprogram the chromatin of a fully differentiated cell so as to induce it or
dedifferentiate it back to the embryonic stem cell (ESC) form. Such cells which are induced to reprogram
from differentiated form to ESC-form are termed as iPS (Cibelli, 2007). Researchers have managed to
produce iPSs from differentiated human fibroblasts by transfecting them (viral-mediated) with relevant
trans-acting factors. Two groups have recently made use of Oct3/4, Sox2, c-Myc, Klf4 (Takahashi et al.,
2007) as well as Oct4, Sox2, Nanog, Lin28 (Yu et al., 2007) respectively to reprogram human somatic
cells into iPS. These reprogramming breakthroughs are exciting since they promise an ethical source of
HESCs which in future may further develop to give patient-specific iPS (Cibelli, 2007). However, this
initiative of replacing HESCs with iPSs has still a long way to go. There are many problems such as
teratoma formation, immune-rejection etc. which still need to be addressed (Cibelli, 2007). Further, the
researchers need to prove the complete ‘stemness' of these iPS cells. However, in light of current
standing iPS do offer new vistas for advancement of regenerative medicine.
Conclusion
Human Embryonic Stem Cells have enormous potential yet the research relating to them has been
crippled largely due to the ethical debate against them. These ethical concerns have been the reason
behind recent initiative to find alternatives for HESCs in regenerative medicine. Of all the alternatives
proposed for HESCs most impressive ones have been, induced Pluripotent Stem-Cells, Amniotic Fluid
Stem-Cells, Umbilical Cord Blood Stem-Cells and Adult Stem Cells. For a particular alternative to replace
HESCs in regenerative medicine, it ought to have almost all properties of HESCs along with other
properties like non-immunogenic and non-teratomic nature. These cells have tremendous potential as
well as power and they need to be handled carefully. Present trends have proved to be encouraging and
it's expected that in coming years there would be more such breakthroughs, which would allow
researchers to replace HESCs with other alternative stem cells. Such breakthroughs may revolutionarize
the field of regenerative medicine and provide relief to millions of patients who are currently in need of
stem cell based treatments.
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